# OnCo record nct07005128 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07005128/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07005128", "NCT07005128" ;
  schema:name "A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small"@en ;
  schema:alternateName "DeLLphi-312"@en ;
  schema:description "A phase 3 trial of Tarlatamab, Durvalumab, Carboplatin in small-cell lung cancer, run by Amgen, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07005128/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07005128> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-08-18" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/> ;
  onco:companies <https://onco.cc/companies/amgen/> .